HL-21

HL-21 is a hybrid liposome formulation composed of dimyristoylphosphatidylcholine (DMPC) and polyoxyethylene (21) dodecyl ether (C12(EO)21). It has been studied primarily as an experimental therapeutic agent for primary effusion lymphoma (PEL), an aggressive neoplasm associated with Kaposi sarcoma-associated herpesvirus/human herpesvirus 8 infection. HL-21 accumulates selectively in the membranes of PEL cells, increases membrane fluidity, induces caspase-3 activation, and triggers apoptosis. Preclinical studies have shown that HL-21 can inhibit PEL cell proliferation in vitro and suppress tumor growth in vivo without significant systemic toxicity. There is also mention of its investigation as a SARS-CoV-2 papain-like protease (PLpro) inhibitor; however, the main published data focus on its anti-cancer properties[1].

Other names

hybrid liposome 21HL21HL-21HL 21